ArticleHaematologica2026
Article in Haematologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Increasing TET Expression and 5-Hydroxymethylcytosine Formation by a Carbocyclic 5-Aza-2'-deoxy-cytidine Antimetabolite.Angewandte Chemie (International ed. in English) · 2026Article
- Silver bullets for the golden age: treatingHaematologica · 2026Article
- Diagnosis of pulmonary infiltration by acute monocytic leukemia via routine cytological examination of bronchoalveolar lavage fluid: A case report.CytoJournal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
33 authors.
Funding
Abstract
Mutations of isocitrate dehydrogenase (IDH) are recurrent in newly diagnosed acute myeloid leukemia (AML) and their prevalence increases with age. The prognostic impact of IDH mutations in AML remains controversial. IDH inhibitors generally have a favorable side-effect profile, making them an attractive option for older patients. This retrospective analysis aimed to describe the prevalence and prognostic impact of IDH mutations in a large cohort of newly diagnosed AML patients aged ≥60 years enrolled in the Beat AML clinical trial. A total of 1,023 patients were included. IDH mutations were detected in 28% of patients, including 9.7% with IDH1mut, 18.9% with IDH2mut, and 1.0% with mutations in both IDH1 and IDH2. IDH mutations frequently co-occurred with DNMT3A (38%), NPM1 (35%), and SRSF2 (34%) mutations. In patients treated with intensive chemotherapy, IDH mutations were not prognostic for overall survival (OS) (P=0.76), while OS was longer for patients with IDH2mut compared to IDHwt in patients treated with hypomethylating agent (HMA)-based therapy (median OS, 18.5 vs. 10.2 months, P<0.001). IDH1 was not significant for outcome. IDH2 remained prognostic for OS after exclusion of patients receiving an IDH inhibitor (hazard ratio=0.60, 95% confidence interval: 0.41-0.89). Outcomes with TP53 or myelodysplasia-related gene mutations were also better with an IDH co-mutation (P=0.043, and P=0.006, respectively). In patients treated with HMA plus venetoclax (N=243), IDHmut was not prognostic (P=0.42). The high prevalence of IDHmut and favorable impact in patients treated with HMA-based therapy supports studies investigating the addition of targeted therapies to HMA-based regimens for older patients with IDH-mutant AML; mut: mutated; wt: wild-type.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.